- In March 2025, Abbott Laboratories launched its new HIV-1 and HIV-2 rapid diagnostic test, designed to provide accurate results in under 15 minutes. This test combines a simple, portable platform with enhanced sensitivity and specificity, catering to both healthcare settings and community-based screenings, especially in resource-limited areas
- In February 2025, Roche Diagnostics introduced its Cobas 6800/8800 system upgrade, offering improved high-throughput capabilities for hepatitis C testing. The new system significantly reduces the time required for results and enhances automation, providing faster diagnosis in clinical laboratories while supporting large-scale testing efforts
- In January 2025, the World Health Organization (WHO) announced the expansion of its HIV self-testing program across sub-Saharan Africa, aimed at increasing early diagnosis rates. This initiative encourages individuals to take control of their health by providing at-home testing kits that offer confidential results and linkage to care services
- In November 2024, Cepheid launched a new molecular diagnostic platform, the GeneXpert Ultra, which can detect both HIV and hepatitis B and C viruses with high accuracy in just a single test. The platform’s portability and ease of use make it particularly beneficial for point-of-care testing in remote areas, further driving the market for decentralized testing solutions
- In April 2024, the NHS in England launched an expanded testing initiative aimed at eliminating hepatitis C by 2025. This initiative includes the deployment of portable testing units, liver scanning technologies, and outreach programs in high-risk communities such as GP surgeries and drug and alcohol support services
